Follistatin 315

Follistatin 315 – Benefits & Side Effects

Follistatin 315 – Protocol

Follistatin 315 – Lifestyle Considerations

Proper Peptide Storage

Why Proper Peptide Storage Matters

Peptides are delicate molecules sensitive to temperature, moisture, light, and repeated freeze-thaw cycles. Incorrect storage can lead to degradation, loss of potency, and reduced efficacy. Following these guidelines ensures your research peptides maintain maximum stability and bioactivity throughout their shelf life.

Lyophilized (Powder) Peptides

Optimal Storage:

• Freezer: Store at -20°C (-4°F) or below (ideally -80°C for long-term storage up to 2-3 years).
• Short-term: Refrigerate at 2-8°C (35.6-46.4°F) for weeks to months.
• Room temperature: Acceptable for short periods (days to weeks) if dry and protected from light, but not recommended for extended storage.
• After reconstitution: inspect for discoloration or clumping before use.

Key Practices:

• Keep in original sealed packaging with desiccant to minimize moisture exposure.
• Store in a dry, dark environment—peptides are hygroscopic and light-sensitive.
• Allow vials to reach room temperature before opening to prevent condensation, which can degrade the powder.

Reconstituted (Liquid) Peptides

Refrigeration is Essential:

• Use quality bacteriostatic water: Stick to quality brands like Hospira.
• Store at 2-8°C (35.6-46.4°F) immediately after reconstitution.
• Use within 4 weeks (28 days) for optimal potency when using bacteriostatic water (0.9% benzyl alcohol).
• Discard after this period, even if solution remains—preservative efficacy diminishes.

Important Warnings:

• Do NOT freeze reconstituted solutions—freezing denatures peptides.
• Avoid freeze-thaw cycles—they cause irreversible degradation. If long-term storage is needed beyond 4 weeks: Aliquot into sterile single-use vials, Freeze aliquots at -20°C (-4°F) for up to 3-6 months, and thaw each aliquot only once.

Handling Peptides Best Practices

1. Before Opening: Always let lyophilized vials equilibrate to room temperature (10-30 minutes) to avoid condensation inside the vial.
2. Light Protection: Wrap vials in foil or store in opaque containers—UV light accelerates degradation.
3. Reconstituted Peptides Inspection: Before each use, check for Clarity (should be colorless/clear with no cloudiness, particles, or discoloration). Discard if any issues observed.
4. Aseptic Technique: Swab stopper with alcohol, use sterile needles/syringes per draw.
5. Labeling: Mark reconstitution date on vials.

Common Peptide Storage Mistakes to Avoid

• Moisture Exposure: Never store open vials; always reseal tightly.
• Temperature Fluctuations: Avoid door storage in fridge/freezer.
• Heat/Light: Keep away from direct sunlight, heaters, or lab lights.
• Overuse of Multi-Dose Vials: Follow 28-day rule per USP/CDC guidelines.
• Freezing Liquids: Repeated cycles can reduce potency by 25%+ per cycle.

Special Peptide Considerations

• Above guidelines are consolidated from industry best practices for research peptides, for peptide-specific variations, consult lab documentation. Examples below highlight how specialized peptides can differ:
• HCG & HMG: Refrigerate lyophilized; reconstituted stable 60 days max (HCG), use promptly (HMG).
• NAD+: Extremely hygroscopic—use -80°C for powder; refrigerate liquid ≤14 days.
• PT-141: Room temp stable short-term; refrigerate reconstituted ≤1 week.

Subcutaneous Peptide Injection Protocol

Subcutaneous Peptide Injection Protocol Overview

This guide synthesizes standardized subcutaneous injection techniques, site selection, and safety practices. Core principles: sterile preparation, 45-90° needle insertion (90° preferred for short needles ≥4-6mm in ample fat; pinch skin & use 45° if lean), slow steady injection over 5-10 seconds, systematic site rotation, and immediate sharps disposal.

Preparation & Supplies

• Hand Hygiene: Wash thoroughly with soap and water.
• Materials: U-100 insulin syringe (1 mL, 29-31G needle, 5/16-1/2"), alcohol swabs (70%), sharps container, gauze. Use 30-50 unit syringes for volumes <10 units.
• Vial Prep: Wipe stopper, dry 10-30 seconds, draw dose, tap out air bubbles. Warm vials to room temperature to reduce stinging.
• Volume Limit: ≤1.5 mL per site; split larger doses (e.g., 75 IU into 3x25 IU). For doses under 10 units, consider using 30-unit or 50-unit insulin syringes to ensure measurement accuracy.

Site Selection & Rotation

Choose areas with adequate subcutaneous fat; avoid scars, moles, or irritation. Systematically rotate sites 1-1.5 inches apart; avoid same spot for 1-2 weeks. Log sites to prevent lipohypertrophy/lumping:

• Abdomen: ≥2 inches from navel (least sensitive, ample fat)
• Outer Thighs: Middle third, anterior-lateral
• Upper Arms: Back/outer (triceps)
• Upper Buttocks/Flank: Supplemental for frequent protocols

Peptide Injection Technique

Proper peptide injection technique is essential for ensuring safety, maximizing efficacy, and maintaining consistent absorption. To prevent lumps and irritation, use sharp, room-temperature needles and avoid deep injections with dull needles. Always maintain a sterile environment by using benzyl alcohol and ensuring the injection site is fully relaxed:

1. Clean site outward in circles; air-dry 30 seconds.
2. Pinch 1-2 inch skin fold to lift subcutaneous layer.
3. Insert needle at 45-90° angle (90° for ample fat, 45° for lean/thin needle).
4. No aspiration (pulling back plunger to check for blood)
5. Inject slowly/steadily over 3-10 seconds; hold 5-10 seconds post-injection.
6. Withdraw at same angle; gentle pressure if bleeding.
7. Dispose in sharps container immediately; never recap.
8. Discard any reconstituted solution if it becomes cloudy. Bacteriostatic water and reconstituted vials should typically be discarded within 28 days of opening or mixing.

Peptide Injection Timing Consideration

• Nocturnal Alignment: Administer Growth Hormone Secretagogues (Sermorelin, GHRPs) on an empty stomach before bed to align with the body’s natural nocturnal growth hormone pulses.
• Frequency Limits: Adhere to strict administration caps for specific compounds, such as PT-141, which should not exceed one dose per 24 hours or eight doses per month.
• Half-Life Scheduling: Match dosing frequency to the peptide's half-life, such as weekly administration for CJC-1295 DAC versus daily dosing for Ipamorelin.
• Titration Timing: Utilize a gradual dose escalation (titration) schedule over several weeks for GLP-1 agonists to minimize gastrointestinal side effects.
• Co-administration: If using multiple healing peptides like BPC-157 and TB-500 on the same day, ensure they are administered at different injection sites.
• Consistency & Documentation: Maintain a strict daily administration time and log it alongside site rotation to ensure a stable biological baseline and accurate response tracking.

Peptide Post-Injection Care & Risks

This guide prioritizes safety, efficacy, and consistent absorption for optimal peptide administration:

• Monitor for redness/swelling; rest site 1-7 days if severe.
• No massage (disrupts absorption).
• Document dose, site, time, reactions.
• Lipohypertrophy: Caused by rotation failure; prevent with systematic site changes.
• Pain/Lumps: From deep injection, cold solution, or dull needles.
• Infection: Maintain asepsis; monitor for fever/redness.

Follistatin 315 – Identification

Common Names: Follistatin 315, Follistatin-315, FS315, FST-315, Follistatin isoform 315, Activin-Binding Protein (ABP), FSH-Suppressing Protein (FSP)

CAS Number: 214047-00-4 (for palmitoylated derivative); 10068-24-7 (for native follistatin); not universally standardized across all suppliers

Molecular Formula: C₁₅₈H₂₅₁N₄₇O₆₀S₁ (estimated for glycosylated native protein); variations exist depending on glycosylation state and salt form

Molecular Weight: ~35 kDa for recombinant protein; 32,000-35,000 Da for native protein depending on glycosylation degree

Origin & Type Classification:

• Source: Natural; products from alternative splicing of the FST gene (UniProt P19883)

• Biosynthesis: Ribosomal; translated from mRNA generated by alternative splicing of transcripts from a single FST gene locus

• Functional Class: Glycoprotein; TGF-β superfamily inhibitor; myostatin antagonist; activin-binding protein; growth factor regulator

Additional Information:

• Amino Acid Sequence: Mature sequence: Gly30 to Trp344 (314 amino acids); N-terminal domain (residues 30-92), three follistatin modules (FS modules 1-3), C-terminal extension (acidic tail unique to FS315)

• Sequence Length: 315 amino acids (mature protein after signal peptide cleavage from 344-amino acid precursor)

• Structural Type: Monomeric glycoprotein; contains 36 cysteine residues forming multiple disulfide bonds creating structural domains characteristic of mosaic proteins

• Post-translational Modifications: N-linked and O-linked glycosylation; can undergo proteolytic processing to generate shorter isoforms (FS288, FS300)

• Salt Form: Available as recombinant protein in PBS (phosphate-buffered saline); lyophilized formulations common; acetate, trifluoroacetate, or hydrochloride salts used in research

• Key Structural Features: Highly acidic C-terminal tail (27 amino acids) that masks heparan sulfate-binding motif, making FS315 the circulating/systemic form; three FS domains (73-75 amino acids each) containing the 10-cysteine motif found in extracellular matrix proteins

• Known Synonyms: FS-315, FST-315, Follistatin protein isoform 315, Activin inhibitor

• Supplier Identification Variations: Recombinant human follistatin 315 commonly expressed in HEK293 cells with C-terminal His-tag; some preparations include N-terminal Met-tag; UniProt ID P19883 for human FST gene product

Database Links:

• PubChem: CID 178101631 (full follistatin protein); CID 5281027 (generic follistatin entry)

• UniProt: P19883 (human FST gene product; includes FS288, FS300, FS315 isoforms from alternative splicing)

• PDB: 2P6A (FS315-Activin A complex structure; Lerch et al., 2007)

• NCBI: Gene ID 10468 (human FST gene); NCBI taxonomy structure available for follistatin

Important Note: FS315 structure uniquely contains the acidic C-terminal extension encoded by exon 6, which critically distinguishes it from FS288. This structural difference results in different tissue localization and biological roles, with FS315 serving primarily as a circulating systemic antagonist of activin, while FS288 functions more in local tissue interactions.

Follistatin 315 – Research

Study: Follistatin Gene Delivery Enhances Muscle Growth and Strength
Benefits: significant increases in muscle mass, creates "super-muscles" by blocking growth limits, circulating form reaches whole body.
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC2852878/
Summary: Your body has a natural brake pedal for muscle growth called "myostatin," which stops you from getting too bulky. Follistatin 315 is the protein that cuts that brake line. Unlike other versions that get stuck to the walls of your cells, Follistatin 315 floats freely in the blood (circulation), meaning it can travel to muscles all over the body. In this study, animals treated with Follistatin 315 saw their muscles grow massive—up to 40-60% larger—without any exercise. Crucially, the muscle wasn't just "puffy"; it was strong and functional. The 315 version is special because it has a "tail" that hides it from sticky cell surfaces, allowing it to stay in the blood longer to do its job. It’s the ultimate muscle-building signal.

Study: Bone Geometry Is Altered by Follistatin-Induced Muscle Growth
Benefits: Strengthens bones to support new muscle, changes bone shape to handle more weight, prevents injury.
Link: https://pubmed.ncbi.nlm.nih.gov/33869993/
Summary: If you put a Ferrari engine in a bicycle, the frame would break. Similarly, if muscles get too strong too fast, they could snap the bone. This research checked if Follistatin 315 caused that problem. Good news: it didn't. When the peptide caused muscle hypertrophy (growth), the bones naturally adapted by changing shape and getting stronger at the attachment points (like the tibia). This proves that the body works as a system; the signal from Follistatin 315 doesn't just make you swole, it triggers a "whole body" upgrade so your skeleton can handle the new power. This is important for treating muscle-wasting diseases where bones often become brittle.

Study: Follistatin-Based Molecule Increases Muscle Regeneration After Injury
Benefits: Speeds up healing of torn muscles, reduces inflammation, and restores strength faster than natural recovery.
Link: https://pubmed.ncbi.nlm.nih.gov/24627466/
Summary: Recovering from a torn muscle usually takes weeks. Researchers tested a version of Follistatin 315 on injured muscles and found it acted like a super-healer. It controlled the early inflammation (swelling) and helped the muscle stem cells (satellite cells) multiply faster. The treated muscles repaired themselves with less scarring and more healthy fiber. This suggests that Follistatin 315 isn't just for building bodybuilder size, but could be a game-changer for athletes recovering from surgery or tears, getting them back on the field in record time.

Follistatin 315 – Research Links